fig1

Final results of a 2:1 control-case observational study using interferon beta and interleukin-2, in addition to first-line hormone therapy, in estrogen receptor-positive, endocrine-responsive metastatic breast cancer patients

Figure 1. Progression-free survival correlated with hormonal therapy (survival median time of HIT 33 months (95%CI: 24-42); survival median time of HT 18 months (95%CI: 12-23)) (A). Overall survival correlated with hormonal therapy [survival median time of HIT 81 months (95%CI: 64-99); survival median time of HT 62 months (95%CI: 54-70)] (B).

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/